SureTrader SureTrader Nadex Advertisement SureTrader
Home > Boards > US OTC > Cannabis >

Cannabics Pharmaceuticals Inc. (CNBX)

Add CNBX Price Alert      Hide Sticky   Hide Intro
Moderator: captainscotty, Quokkie, WallyWest
Search This Board: 
Last Post: 2/22/2017 8:20:07 PM - Followers: 116 - Board type: Free - Posts Today: 107


U.S OFFICE: , 3 BETHESDA METRO CENTRE, BETHESDA, MARYLAND, 20814(877) 424-2429[email protected]


Cannabics Pharmaceuticals is dedicated to the development of Personalized Anti-Cancer treatments.

Our main focus is the development of novel therapies and biotechnological tools aimed to providing relief from diverse ailments and treat human malignancies. These advanced tools include novel delivery systems, personalized medicine diagnostics and therapies based on Cannabinoid compounds.

Cannabics scientific research is devoted to create tailored therapies for cancer patients, utilizing advanced High-throughput screening (HTS) diagnostics and personalized bioinformatics tools.

The Company’s principal product is Cannabics SR' a long acting oil capsule that provides a safe, effective and reliable administration of cannabis. Composed solely from food grade materials, Cannabics SR' 5-10mg delivers a steady level of beneficial effects for 4–8 hours.

Cannabics Pharmaceuticals Inc. is traded in the US OTC stock exchange, under the trade symbol: CNBX


October 20, 2016 Cannabics Pharmaceuticals Discovers Specific Ratios of THC/CBD Effectuate Reduction in U87MG Glioblastoma Cell Viability

September 28, 2016 How this tiny Middle Eastern nation came to lead the world in medical marijuana research

June 6, 2016, Cannabics Pharmaceuticals has Filed a PCT Application, Covering a Novel Personalized Anti-Cancer Diagnostics System.


"Cannabics SR', is a long acting oil capsule that provides a safe, effective and reliable administration of cannabis."


Cannabics SR' Capsules, Technology Description - Route of administration


There is a growing number of patients, worldwide, who could benefit from the therapeutic properties of cannabinoids. The unmet need of these patients is a safe, standardized and easy to administer cannabinoid-based therapy. Cannabinoid administration is mainly through smoking, vaporizing, sublingual and oral. While clinical studies show contradictory data regarding a correlation between smoking cannabis and respiratory diseases, most physicians agree that smoking medical cannabis, while having its benefits, is not a healthy nor standardized therapy. 

The pharmacokinetics of THC varies as a function of its route of administration. Pulmonary assimilation of inhaled THC causes a maximum plasma concentration within minutes; psychotropic effects start within seconds to a few minutes, reach a maximum after 15–30 minutes, and taper off within 2–3 hours. Following oral ingestion, psychotropic effects set in with a delay of 30–90 minutes, reach their maximum after 2–3 hours and last for about 4–12 hours, depending on dose and specific effect. Another common route of administration is sublingually. Pure cannabinoids are extracted from the raw plant, dissolved in different oils and administered with a dropper. The beneficial effect of sublingual oil administration is 2-4 hours with a fast onset due to quick absorption through the oral cavity.

The most common oral administration of cannabinoids is through eating edibles, mainly, cookies, chocolate bars and lozenges. Since absorption is attenuated when cannabinoids are ingested orally, Edibles usually contain high dosages of cannabinoids (50-300mg). The high dosage may cause undesirable side effects, mainly, dizziness, anxiety and dissociation. These side effects cause many patients to withdraw from the therapeutic process.  The oral administration route has the longest beneficial effect (4-8 hours) and lacks the undesirable effects of smoking.

Technology currently envisions the licensing of three different formulations: capsules with a 10:1 CBD to THC ratio, a 10:1 THC to CBD ratio and a balanced formulation with 1:1 THC:CBD.

Cannabics Pharmaceuticals Inc. does not manufacture, distribute, dispense or possess any controlled substances, including cannabis or cannabis based preparations.
CNBX Security Details
Share Structure
  Market Value1 $72,404,107 a/o Jan 13, 2017
Authorized Shares 900,000,000 a/o Dec 30, 2016
Outstanding Shares 107,265,344 a/o Dec 30, 2016
-Restricted 90,368,887 a/o Dec 30, 2016
-Unrestricted 16,896,457 a/o Dec 30, 2016
  Held at DTC Not Available
Float 14,295,638 a/o Jun 30, 2016
  Par Value 0.0001

CNBX Security Details
Share Structure
  Market Value1 $37,994,466 a/o Oct 28, 2016
  Authorized Shares 900,000,000 a/o Jul 09, 2015
  Outstanding Shares 107,026,665 a/o Jun 30, 2016
  -Restricted Not Available
  -Unrestricted Not Available
  Held at DTC Not Available
  Float 18,737,071 a/o Jun 30, 2016
  Par Value 0.0001

Cannabics Pharmaceuticals Inc. is a US based company founded in 2012 by Israeli researchers from the fields of molecular biology and cancer.
The Company's scientific focus is on harnessing the proven therapeutic properties of natural Cannabinoids and to create tailored therapies for cancer patients, utilizing advanced HTS technology and personalized bioinformatics tools.
The Company's R&D is based in Israel, where it is fully licensed by The Ministry of Health and involves both scientific and academic research as well as current ongoing medical clinical studies which are registered with the US NIH.

The Company new clinical study examine the effectiveness of Cannabics SR capsules as treatment to improve cancer related CACS (Cachexia and Anorexia) in advanced cancer Patients. While this study is taking place in Israel, it is fully registered with the US NIH under "Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients", identifier NCT02359123 and can be found at:

What is A Cannabinoid?

You’ve heard by now that marijuana is a powerful medicinal herb. But, just how powerful is it? The list of medical benefits for these top 10 cannabinoids seems endless.


Cannabics Pharmaceuticals Announces a New Dosage of 5mg THC Cannabis Capsule Treating Cancer Patients Suffering from Cachexia and Anorexia Syndrome...!

BETHESDA, Maryland, Jan. 3, 2017 /PRNewswire/ -- Cannabics Pharmaceuticals Inc. (CNBX) today announced development of Cannabics 5mg THC Capsule intended for naïve patient who have not tried cannabis in the past.

Dr. Eyal Ballan, Chief scientist of Cannabics Pharmaceuticals stated, "Our mission is to find the right balance between efficacy on the one hand and the elimination of undesired psychoactive effects on other."

The Cannabics 5mg THC capsule is currently being evaluated by the company in a clinical study as a palliative treatment, which is conducted by the oncology department at the prestigious Rambam Medical Center in northern Israel and under strict regulations of the Ministry of Health, by whom Cannabics Pharmaceuticals has been licensed since 2014.

The study is taking place in Israel, it is fully registered with the US NIH under "Cannabics Capsules as Treatment to Improve Cancer Related CACS in Advanced Cancer Patients", Identifier NCT02359123, and may be found at :

"The majority of our cancer trial patients have no previous experience with Cannabis, hence this recalibration of the THC level may be more amenable. We believe there is a significant potential medical market for our 5mg THC capsule in countries that have now instituted medical cannabis regulations," said Itamar Borochov, CEO of Cannabics Pharmaceuticals Inc.


<img alt="" data-cke-saved-src=""="" rel="nofollow" target="_blank">"; style="height:398px; width:400px">


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
CNBX News: Israeli Innovation is at the Heart of a Growing Cannabis Ecosystem 02/08/2017 08:30:00 AM
CNBX News: Quarterly Report (10-q) 01/17/2017 12:03:56 PM
CNBX News: Report of Proposed Sale of Securities (144) 12/21/2016 02:05:02 PM
CNBX News: Annual Report (10-k) 12/13/2016 01:59:15 PM
CNBX News: Current Report Filing (8-k) 12/13/2016 01:55:24 PM
#568  Sticky Note Cannabics Pharmaceuticals Announces a New Dosage of 5mg captainscotty 01/15/17 09:13:10 PM
#1184   My earlier close prediction today of $4.40 was amaintrader 02/22/17 08:20:07 PM
#1183   My opinion its get a cbis chart ..and jpowellvlc 02/22/17 05:11:29 PM
#1182   Haha I was just saying the bounce back MoFlowMoCash 02/22/17 05:09:31 PM
#1181   Meaning this will go up or down in Goodtimes79 02/22/17 04:37:20 PM
#1180   MoFlow, the link was dead for me. jim992 02/22/17 04:29:16 PM
#1179   Hell out will be tomorrow.. jpowellvlc 02/22/17 03:46:42 PM
#1178   CNBX holding up strong $5+ open possible again ClearlyStocks 02/22/17 03:22:11 PM
#1177   last chance to get out over $4. Jrock25 02/22/17 03:08:44 PM
#1176   All the mmj stocks in the etf are starkd748 02/22/17 02:53:55 PM
#1175   tomorrow 2.8,,then buyyyyy jpowellvlc 02/22/17 02:27:49 PM
#1174   Still up over $30,000 from yesterday's run. jim992 02/22/17 02:25:29 PM
#1173   I see us closing over $5 Lkelley66 02/22/17 02:19:19 PM
#1172   I think they been covering their short sales amaintrader 02/22/17 02:16:54 PM
#1171   this afternoon is your last chance to get Jrock25 02/22/17 02:12:08 PM
#1170   LOL I just spit up my Mountain Dew Jrock25 02/22/17 02:11:08 PM
#1169   CNBX $4.90 goes $5+ hedge funds begin to ClearlyStocks 02/22/17 01:56:57 PM
#1168   intraday traders.. jpowellvlc 02/22/17 01:54:04 PM
#1167   hey no problem at all. Jrock25 02/22/17 01:53:28 PM
#1166   CNBX $4.80 wow. Buys over the ask. ClearlyStocks 02/22/17 01:48:06 PM
#1165   Don't be bag holder. Will close around $4.40 amaintrader 02/22/17 01:46:57 PM
#1164   Here's to hoping. I'm in at $3.75 so cheers! Goodtimes79 02/22/17 01:25:54 PM
#1163   Well said!!! Midnightmatt 02/22/17 01:17:05 PM
#1162   nice trade. I view every bounce Jrock25 02/22/17 01:14:30 PM
#1161   Hi Jrock, jim992 02/22/17 01:13:24 PM
#1160   I am just curious, how do you short stock1ings 02/22/17 12:58:47 PM
#1159   I nailed that $7.40 call by the nose. jjr04001 02/22/17 12:58:21 PM
#1158   I am in at 3.77 I think we Lkelley66 02/22/17 12:55:09 PM
#1157   I think CNBX closes $5+ ClearlyStocks 02/22/17 12:45:22 PM
#1156 MoFlowMoCash 02/22/17 12:44:40 PM
#1155   Pump n dump... Bud_Fox1 02/22/17 12:31:28 PM
#1154   why you chosed this price ? 10 ma ? balamidas 02/22/17 12:22:50 PM
#1153   I'm in for a few 100 looking for @MomoPicks 02/22/17 12:19:59 PM
#1152   Not surprised one bit by this dump, this yaboy520 02/22/17 12:18:56 PM
#1151   Yep adding some here MoFlowMoCash 02/22/17 12:15:48 PM
#1150   Wouldn't be surprised if CNBX ended up going ClearlyStocks 02/22/17 12:08:33 PM
#1143   Huge dip here. WOW. Buying op for sure. GLTA BAD HEMPER 02/22/17 11:46:12 AM
#1142   Sold part and covered the cost of all Triple9 02/22/17 11:44:33 AM
#1141   CNBX vs VDRM(MJ pharmaceutical stocks comparisons) legalizeMJ 02/22/17 11:44:02 AM
#1140   Why are you sorry for them? They get mattp_160 02/22/17 11:39:41 AM
#1139   It was only junk if you lost money mattp_160 02/22/17 11:39:02 AM
#1138   Hate to say it, she's going down to $2.77ish mattp_160 02/22/17 11:38:01 AM
#1136   I'm sorry for longs that are still in Jrock25 02/22/17 11:31:12 AM
#1135   SELL or HOLD??? in at 2.40. expected snj_M0ney_team 02/22/17 11:31:08 AM
#1134   That was rude ProjectTurbo 02/22/17 11:30:40 AM
#1133   I will buy 3,s or less jpowellvlc 02/22/17 11:26:50 AM
#1132   Curious, because of RSI or a hunch? Goodtimes79 02/22/17 11:20:33 AM
#1131   So far I was pretty spot on.... More @MomoPicks 02/22/17 11:17:47 AM
#1130   take a wild guess who is selling to Jrock25 02/22/17 11:13:37 AM
#1129   haha lucky you! huge patent approvals already....I stockman69 02/22/17 11:09:22 AM
#1127   I sold at $7 bought back @4.80 =] $$$ chucky6540 02/22/17 11:06:30 AM